Most Recent Additions*
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Philip Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, and Xenofon Baraliakos
Outcomes of Patients Transferred to Tertiary Care Centers for Treatment of Cardiogenic Shock: A Cardiogenic Shock Working Group Analysis.
A Reshad Garan, Rachna Kataria, Borui Li, Shashank Sinha, Manreet K Kanwar, Jaime Hernandez-Montfort, Song Li, VAN-Khue Ton, Vanessa Blumer, E Wilson Grandin, Neil Harwani, Peter Zazzali, Karol D Walec, Gavin Hickey, Jacob Abraham, Claudius Mahr, Sandeep Nathan, Esther Vorovich, Maya Guglin, Shelley Hall, Wissam Khalife, Paavni Sangal, Yijing Zhang, Ju H Kim, Andrew Schwartzman, Alec Vishnevsky, Daniel Burkhoff, and Navin K Kapur
Improvement: Increasing staff and patient awareness of and knowledge of genetic therapy research
JE Milton, A Chavez, K Kuykendall, and AA Lambert
Comparison of in-clinic only to in-clinic plus virtual mental health screens of adults with cystic fibrosis during SARS-CoV-2 pandemic
KG Mertz, M Ingoldby, T Vance, and AA Lambert
UCSB Pharmacology Colloquium
Rexinoids in Breast Cancer Prevention
Primary Immunoprevention Strategies
First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)
*Updated as of 12/08/23.